Literature DB >> 7646916

Plasma tetranectin and colorectal cancer.

C K Høgdall1, M Christiansen, B Nørgaard-Pedersen, S M Bentzen, O Kronborg, I Clemmensen.   

Abstract

The prognostic significance of plasma tetranectin (PL-TN) in colorectal cancer was retrospectively examined in 504 patients (80 Dukes' A, 174 Dukes' B, 98 Dukes' C and 152 Dukes' D). Follow-up time was 7-12 years. No significant prognostic variable was found for Dukes' A patients by Cox multivariate analysis. In stage B, PL-TN was the second strongest prognostic variable [relative hazard (RH) = 3.3 for patients with PL-TN < or = 7.5 mg/l]. The other prognostic variables were perineural invasion (RH = 3.7), tumour distance < or = 10 cm from the anal verge (RH = 3.0), postoperative radiotherapy (RH = 2.9) and a high carcinoembryonic antigen (CEA) score (RH = 1.8). In Dukes' C, only CEA score and gender were of prognostic significance. For Dukes' D, PL-TN was the only prognostic variable (RH = 1.7). Testing all patients in one multivariate analysis, Dukes' staging was the strongest and PL-TN the second strongest prognostic variable. The shortened survival for patients with low PL-TN levels is illustrated with lifetables.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7646916     DOI: 10.1016/0959-8049(94)00520-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  8 in total

1.  Expression and prognostic significance of Tetranectin in invasive and non-invasive bladder cancer.

Authors:  A Brunner; C Ensinger; M Christiansen; S Heiss; I Verdorfer; G Mikuz; A Tzankov
Journal:  Virchows Arch       Date:  2007-04-13       Impact factor: 4.064

2.  Identification of tetranectin as a potential biomarker for metastatic oral cancer.

Authors:  Martha E Arellano-Garcia; Roger Li; Xiaojun Liu; Yongming Xie; Xiaofei Yan; Joseph A Loo; Shen Hu
Journal:  Int J Mol Sci       Date:  2010-09-02       Impact factor: 5.923

3.  Plasma proteome analysis of cervical intraepithelial neoplasia and cervical squamous cell carcinoma.

Authors:  Mee Lee Looi; Saiful Anuar Karsani; Mariati Abdul Rahman; Ahmad Zailani Hatta Mohd Dali; Siti Aishah Md Ali; Wan Zurinah Wan Ngah; Yasmin Anum Mohd Yusof
Journal:  J Biosci       Date:  2009-12       Impact factor: 1.826

4.  Aberrant tetranectin expression in human breast carcinomas as a predictor of survival.

Authors:  P Obrist; G Spizzo; C Ensinger; D Fong; T Brunhuber; G Schäfer; M Varga; R Margreiter; A Amberger; G Gastl; M Christiansen
Journal:  J Clin Pathol       Date:  2004-04       Impact factor: 3.411

5.  Exome-wide Association Study Identifies CLEC3B Missense Variant p.S106G as Being Associated With Extreme Longevity in East Asian Populations.

Authors:  Kumpei Tanisawa; Yasumichi Arai; Nobuyoshi Hirose; Hiroshi Shimokata; Yoshiji Yamada; Hisashi Kawai; Motonaga Kojima; Shuichi Obuchi; Hirohiko Hirano; Hideyo Yoshida; Hiroyuki Suzuki; Yoshinori Fujiwara; Kazushige Ihara; Maki Sugaya; Tomio Arai; Seijiro Mori; Motoji Sawabe; Noriko Sato; Masaaki Muramatsu; Mitsuru Higuchi; Yao-Wen Liu; Qing-Peng Kong; Masashi Tanaka
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2017-03-01       Impact factor: 6.053

6.  CLEC3B is downregulated and inhibits proliferation in clear cell renal cell carcinoma.

Authors:  Jian Liu; Zhe Liu; Qun Liu; Lina Li; Xiaona Fan; Tao Wen; Guangyu An
Journal:  Oncol Rep       Date:  2018-07-23       Impact factor: 3.906

7.  Exosomal proteomic signatures correlate with drug resistance and carboplatin treatment outcome in a spontaneous model of canine osteosarcoma.

Authors:  Marcus A Weinman; Stephen A Ramsey; Haley J Leeper; Jacqueline V Brady; Andrew Schlueter; Stanislau Stanisheuski; Claudia S Maier; Tasha Miller; Carl E Ruby; Shay Bracha
Journal:  Cancer Cell Int       Date:  2021-05-01       Impact factor: 6.429

8.  Tetranectin Binds to the Kringle 1-4 Form of Angiostatin and Modifies Its Functional Activity.

Authors:  Tirsit Mogues; Michael Etzerodt; Crystal Hall; Georg Engelich; Jonas H. Graversen; Kevan L. Hartshorn
Journal:  J Biomed Biotechnol       Date:  2004
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.